USA — GE Healthcare has unveiled the MyBreastAI Suite, an innovative all-in-one platform designed to streamline breast cancer detection and enhance workflow productivity for healthcare professionals.
This artificial intelligence (AI) platform is tailored specifically for mammography and integrates three AI applications from iCAD, aimed at facilitating early detection and improving patient outcomes.
The MyBreastAI Suite currently incorporates ProFound AI for DBT, SecondLook for 2D Mammography, and PowerLook Density Assessment AI applications from iCAD.
These applications empower radiology departments by increasing operational efficiency and supporting early detection efforts.
ProFound AI for DBT provides radiologists with essential data such as lesion certainty of finding and case scores.
This information proves invaluable for caseload prioritization, aiding in clinical decision-making, and potentially reducing burnout among healthcare professionals. The application is a crucial tool in the quest for early breast cancer detection.
The SecondLook for 2D Mammography application serves as a computer-aided detection (CAD) system, identifying and highlighting regions of interest in screening and diagnostic mammograms.
Leveraging GE Healthcare’s full-field digital mammography (FFDM) systems, it directs the radiologist’s attention to specific areas following the initial reading, enhancing diagnostic accuracy.
The PowerLook Density Assessment application is strategically designed to simplify the reporting and stratification of patient data.
It aims to reduce variability in breast density assessments conducted by different radiologists.
Additionally, the tool empowers clinicians to provide women with accurate and trustworthy breast density assessments based on AI mammogram analysis.
Pooja Pathak, Vice President and Mammography General Manager at GE Healthcare, emphasized the company’s commitment to leveraging AI in mammography for the early detection of breast cancer.
Pathak stated, “As screening guidelines continue to evolve and more attention is given to personal risk factors such as breast density, these kinds of tools are an important and exciting addition to our comprehensive portfolio of breast imaging technologies.”
According to the medical technology company, the use of these digital solutions can help in clinical decision-making and ranking caseload as per priority.
MyBreastAI Suite will be seamlessly integrated into the Senographe Pristina mammography portfolio and will be distributed, installed, and supported by GE Healthcare.
Initially available in the United States, this platform marks a significant step forward in utilizing AI to transform breast imaging technologies.